RJG-2051 is a selective covalent aldo-keto reductase family 1 member C3 ( AKR1C3 ) inhibitor with an IC 50 value of 13 nM. RJG-2051 interferes with the metabolic process of substrates such as androgens, estrogens, and prostaglandins by AKR1C3. RJG-2051 is promising for research of cancers.
Products | Products > Disease Areas > Cancer | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.